Alta Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Alta Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,144	Closed	-$224K	–	167
2025 Q3	$224K	Sell	4,144 -900	-18%	-$51.5K	0.08%	142
2025 Q2	$277K	Sell	5,044 -2,394	-32%	-$141K	0.13%	97
2025 Q1	$526K	Buy	+7,438	New	+$500K	0.24%	77
2023 Q1	–	Sell	-2,000	Closed	-$207K	–	139
2022 Q4	$207K	Buy	+2,000	New	+$188K	0.14%	138

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Alta Wealth Advisors's BMRN Position: Q4 2025 in Review

Alta Wealth Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 4,144 shares — an estimated $224K sold.

Alta Wealth Advisors first reported a position in BMRN in Q4 2022 and held it in 4 quarters. The position peaked at $526K in Q1 2025. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Alta Wealth Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Alta Wealth Advisors sold 4,144 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $224K.
Alta Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 4 quarters.
Alta Wealth Advisors's BioMarin Pharmaceuticals position peaked at $526K in Q1 2025.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Alta Wealth Advisors's 13F filing for Q4 2025, filed 3 Feb 2026.